PYPD (PolyPid) Change In Payables And Accrued Expense : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Change In Payables And Accrued Expense?

PolyPid's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.00 Mil. It means PolyPid's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Sep. 2024 .

PolyPid's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.85 Mil. It means PolyPid's Accounts Payable & Accrued Expense declined by $0.85 Mil from Dec. 2022 to Dec. 2023 .

PolyPid Change In Payables And Accrued Expense Historical Data

The historical data trend for PolyPid's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Change In Payables And Accrued Expense Chart

PolyPid Annual Data

Trend

Dec12

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-1.09

0.24

4.26

-4.51

-0.85

PolyPid Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

PolyPid Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PolyPid Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of PolyPid's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPid Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.